Takeda mulls Shire acquisition bid
03-04-2018
A US judge handed a win to Shire late last week, finding that a generic version of its attention deficit hyperactivity disorder drug Adderall XR (amphetamine/dextroamphetamine mixed salts) would infringe Shire’s patents.
To continue reading this article and to access our full archive, digital magazines and special reports you will need a subscription.
Start a subscription today to access the LSIPR website
If you have already subscribed please login.
For multi-user price options, or to check if your company has an existing subscription we can add you into, please email Atif at achoudhury@newtonmedia.co.uk
If you have any technical issues please email tech support.
For access to the complete website and archive choose '12 MONTH SUBSCRIPTION'. For a free, two-week trial select ‘TWO WEEK FREE TRIAL’.
Shire, generic, Adderall, ADHD, attention deficit hyperactivity disorder, Abhai, ANDA, litigation, ruling
